Predictive Oncology Files 8-K on Financials
Ticker: AGPU · Form: 8-K · Filed: Nov 13, 2024 · CIK: 1446159
Sentiment: neutral
Topics: financial-reporting, 8-K, company-history
TL;DR
Predictive Oncology dropped an 8-K on Nov 13th - check financials!
AI Summary
Predictive Oncology Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company was formerly known as Skyline Medical Inc. and Precision Therapeutics Inc.
Why It Matters
This 8-K filing provides an update on the company's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Predictive Oncology Inc. (company) — Registrant
- November 13, 2024 (date) — Date of earliest event reported
- Skyline Medical Inc. (company) — Former company name
- Precision Therapeutics Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Predictive Oncology Inc., and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 13, 2024.
What were some of the previous names of Predictive Oncology Inc.?
Predictive Oncology Inc. was formerly known as Skyline Medical Inc. and Precision Therapeutics Inc.
In which state is Predictive Oncology Inc. incorporated?
Predictive Oncology Inc. is incorporated in Delaware.
What is the business address of Predictive Oncology Inc.?
The business address of Predictive Oncology Inc. is 91 43rd Street, Suite 110, Pittsburgh, PA 15201.
Filing Stats: 424 words · 2 min read · ~1 pages · Grade level 10.1 · Accepted 2024-11-13 07:00:33
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value POAI Nasdaq Capital Market
Filing Documents
- f8k_111224.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 78KB
- 0001171843-24-006311.txt ( ) — 295KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_111224_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 13, 2024, Predictive Oncology Inc. issued a press release attached hereto as Exhibit 99.1 announcing its financial results for the quarter ended September 30, 2024.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (a) Not applicable. (b) Not applicable. (c) Not applicable. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: November 13, 2024 By: /s/ Josh Blacher Josh Blacher Interim Chief Financial Officer